Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.
Enanta Pharmaceuticals Price Performance
Shares of NASDAQ:ENTA traded up $0.04 during midday trading on Monday, hitting $13.81. The company had a trading volume of 78,940 shares, compared to its average volume of 195,215. The company has a fifty day moving average of $13.08 and a two-hundred day moving average of $13.42. The company has a market cap of $401.65 million, a price-to-earnings ratio of -5.33 and a beta of 0.98. Enanta Pharmaceuticals has a 12-month low of $6.45 and a 12-month high of $17.15.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG increased its holdings in shares of Enanta Pharmaceuticals by 4.6% in the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Enanta Pharmaceuticals by 8.3% during the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 1,383 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 1,940 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $32,000. 94.99% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on ENTA
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.
Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.
Read More
- Five stocks we like better than Enanta Pharmaceuticals
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
